The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Efficacy and safety results from EMERALD-3: A phase 3, randomized study of tremelimumab plus durvalumab with or without lenvatinib combined with transarterial chemoembolization (TACE) in participants (pts) with unresectable embolization-eligible hepatocellular carcinoma (eeHCC).
 
Ghassan Abou-Alfa
Consulting or Advisory Role - Abbvie; Ability Pharma (I); Agenus (I); Alligator Bioscience (I); Amgen (I); Arcus Ventures (I); Astellas Pharma (I); Astellas Pharma (I); AstraZeneca; Autem Medical; Berry Genomics; BioNtech (I); Boehringer Ingelheim (I); Bristol-Myers Squibb/Medarex (I); Fibrogen (I); Ikena Oncology (I); Immuneering (I); Ipsen; J-Pharma; Merck Serono (I); Merus NV (I); Moma Therapeutics (I); Neogene Therapeutics (I); Novartis (I); Regeneron (I); Revolution Medicines (I); Roche/Genentech; Servier; Syros Pharmaceuticals (I); Tango Therapeutics (I); Tempus (I); Vector Health; Yiviva
Research Funding - Abbvie (Inst); Agenus (Inst); Amgen (Inst); Arcus Ventures (Inst); AstraZeneca (Inst); Atara Biotherapeutics (Inst); Beigene (Inst); BioNtech (Inst); Bristol-Meyer Squibb (Inst); Bristol-Myers Squibb (Inst); Coherus Biosciences (Inst); Digestive Care (Inst); Elicio Therapeutics (Inst); Genentech/Roche (Inst); Helsinn Healthcare (Inst); J-Pharma (Inst); Revolution Medicines (Inst); Yiviva (Inst)
 
Zhenggang Ren
Consulting or Advisory Role - AstraZeneca; MSD
 
Joseph Erinjeri
Consulting or Advisory Role - AstraZeneca
 
Jeong Heo
Honoraria - Roche
Consulting or Advisory Role - AstraZeneca/MedImmune; Medvir; Surrozen
Speakers' Bureau - Abbvie; AstraZeneca/MedImmune; Gilead Sciences; Gilead Sciences; Oncolys BioPharma; Roche; Yuhan
Research Funding - Gilead Sciences; Roche
 
Riccardo Lencioni
Consulting or Advisory Role - AstraZeneca
 
Yasuaki Arai
Consulting or Advisory Role - AstraZeneca; Boston Scientific; Fuji Systems; Guerbet; Sirtex Medical; W.L. Gore & Associates
Speakers' Bureau - Boston Scientific; Canon Medical System; Cardinal Health; Eisai; Merit Medical Systems; Sumitomo Chemical; Terumo International Systems
Patents, Royalties, Other Intellectual Property - Sumitomo Chemical
 
Mohamed Bouattour
Honoraria - Bayer Schering Pharma
Consulting or Advisory Role - Abbvie; AstraZeneca; Bayer; Bristol-Myers Squibb; Eisai; Ipsen; Roche; SERVIER; Sirtex Medical; Taiho Pharmaceutical; TERUMO
Speakers' Bureau - Bayer; Jazz Pharmaceuticals; Roche; SIRTEX Medical
Research Funding - AstraZeneca (Inst); Bayer Schering Pharma (Inst); BMS GmbH & Co. KG (Inst); Incyte (Inst); Merck (Inst); MSD (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Bayer; Ipsen; Roche
 
Maria Gonzalez-Carmona
No Relationships to Disclose
 
Yabing Guo
No Relationships to Disclose
 
Aibing Xu
No Relationships to Disclose
 
Gustavo Alves
Consulting or Advisory Role - AstraZeneca; Merck Serono; MSD Oncology
Speakers' Bureau - AstraZeneca; GlaxoSmithKline; Sanofi
Research Funding - AstraZeneca (Inst); AVEO (Inst); BeiGene (Inst); BMS Brazil (Inst); Janssen Oncology (Inst); MSD Oncology (Inst); Roche (Inst); Sanofi (Inst); Zymeworks (Inst); Zymeworks (Inst)
 
Arunee Dechaphunkul
No Relationships to Disclose
 
Gwo Fuang Ho
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Boehringer Ingelheim; MSD; Novartis; Pfizer; Roche; Tadeka
Speakers' Bureau - AstraZeneca; Boehringer Ingelheim; Eisai; Merck; MSD; Novartis; Pfizer; Roche
Research Funding - AB Science (Inst); Amgen (Inst); Arcus Biosciences (Inst); Astellas Pharma (Inst); AstraZeneca/Daiichi Sankyo (Inst); Boehringer Ingelheim (Inst); EliLily (Inst); Janssen Research & Development (Inst); Merck Sharp & Dohme (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Regeneron (Inst); Roche (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Bristol Myers Squibb; Dr Reddy’s; Ipsen; MSD Oncology; Pfizer; Regeneron; Roche Sequencing Solutions; SERVIER; Zullig Pharma
 
Yueh Ni Lim
Consulting or Advisory Role - AstraZeneca; Pfizer
Speakers' Bureau - Roche
Research Funding - Arcus Biosciences; AstraZeneca; MSD Oncology; Pfizer; Roche; yuhan
Travel, Accommodations, Expenses - Accord Healthcare; Amgen; Eisai; Ipsen; MSD Oncology; Roche; Roche
 
Hongtao Hu
No Relationships to Disclose
 
Sri Harsha Tekumalla
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
 
Vimal Dave
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
 
Xavier Monzoni­s
Employment - AstraZeneca
 
Masatoshi Kudo
Honoraria - AstraZeneca; Chugai/Roche; Eisai
Consulting or Advisory Role - AstraZeneca; Chugai/Roche; Eisai
Research Funding - Eisai (Inst); GE Healthcare (Inst); Otsuka (Inst); Taiho Pharmaceutical (Inst)
 
Jia Fan
No Relationships to Disclose